Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzheng Huayu Tablets in Compensated Metabolic Dysfunction-Associated Fatty Liver Cirrhosis
NCT07663643Phase 4Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- May 2026
- Primary completion
- Oct 2027
01
Overview
Phase 4, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis cirrhosis comparing Fuzheng Huayu Tablets Group with Placebo Group (2 arms). Primary endpoint: Proportion of Patients with >=20% Reduction in Liver Stiffness Measurement at 72 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
fuzheng huayu
03
Conditions
metabolic dysfunction-associated steatohepatitis cirrhosis
Beyond the preview
Go deeper on NCT07663643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07663643.